Based on these findings, we hypothesized that miR‐335 may be the “bridge” to combine ZNF‐148 and SOD2 and that ZNF‐148 may be involved in breast cancer progression by targeting miR‐335/SOD2 signaling. Here, SOD2 is linked to breast cancer.